Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center

@inproceedings{Anger2013EvaluationOR,
  title={Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center},
  author={Kevin E. Anger and Jeremy R Degrado and Bonnie C. Greenwood and Steven A. Cohen and Paul M. Szumita},
  booktitle={Therapeutics and clinical risk management},
  year={2013}
}
PURPOSE Early clinical trials of recombinant human activated protein C (rhAPC) for severe sepsis excluded patients at high risk of bleeding. Recent literature suggests bleeding rates are higher in clinical practice and may be associated with worsened outcomes. Our objective was to evaluate baseline demographics; incidence, and risk factors for major bleeding; and mortality of patients receiving rhAPC for severe sepsis at our institution. METHODS A retrospective study was performed for all… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 31 references

announces withdrawal of Xigris following recent clinical trial results

Lilly. Lilly
Available from: https://investor.lilly.com/releasedetail2. cfm?ReleaseID=617602. Accessed October • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…